reports
Arcturus Therapeutics Holdings Inc: 1 director
A director at Arcturus Therapeutics Holdings Inc sold 17,435 shares at 35.020USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Arcturus Therapeutics to Present at Upcoming Investor and Scientific C...
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: TIDES: Oligonucleotide and Peptide Therapeutics scientific conference PresentationDa...
Arcturus Therapeutics Announces Preclinical Publication of its COVID-1...
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100% protection against SARS-CoV-2 infection following a single vaccination Clinical study remains on track, initial data readout expected Q4 2020 SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant ...
Arcturus Therapeutics Executes Definitive Supply Agreement with the Is...
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health, to supply C...
Arcturus Therapeutics Announces that it has Initiated Dosing of its CO...
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study Potential for highly differentiated COVID-19 vaccine profile with a single administration, at a low dose Clinical study data expected in Q4 2020 SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respirat...
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results ...
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, Phase 1 healthy volunteer study continues to advance, initial results expected Q4 Successfully raised approximately $280 million in gross proceeds through two public equity offerings in 2020 to adva...
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer Nationally recognized leader in corporate life sciences transactions SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020. Mr. Kurata joins Arcturus from Mintz, where h...
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results ...
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020 SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2020 after the market close on August 10 and will also provide a corporate...
Arcturus Therapeutics Announces Closing of Public Offering and Full Ex...
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price ...
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offer...
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share. The gross proceeds of the offering to the Company are...
Arcturus Therapeutics Announces Proposed Public Offering of Common Sto...
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to mark...
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Hea...
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19 Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced a binding term sh...
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Pha...
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19 Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration SAN DIEGO and SINGAPORE, July 21, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicin...
Arcturus Therapeutics Announces the Formation of its Vaccine Platform ...
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics...
Arcturus Therapeutics to be Added to Russell 2000® Index
Arcturus Therapeutics to be Added to Russell 2000® Index SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will be added to the Russell 2000® Index, as part of the 2020 Russell indexes reconstitution. The addition will be effective after the U.S. market opens on June 29, 2020 as part of the 2020 Russell U.S. Indexes annual reconst...
Arcturus Therapeutics to Present at the Raymond James Human Health Inn...
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that Joseph Payne, President and Chief Executive Officer of Arcturus, will present at the Raymond James Human Health Innovation Conference, being held virtually during June 15-18, 2020. Raymon...
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase...
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company’s messenger RNA (mRNA)-based therapeutic candidate for Orni...
Arcturus Reports Additional Supportive Preclinical Data for its COVID-...
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19) New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all doses SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines,...
Arcturus Therapeutics Announces First Quarter 2020 Financial Results a...
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19);New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains on track to begin clinical trial for COVID-19 vaccine this summer Successfully raised net of $75.5 million in secondary common stock offering;Current resources sufficient to support operations for more than two years Investor Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Arctu...
Arcturus Therapeutics to Report First Quarter 2020 Financial Results a...
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020 SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will release its financial results for the quarter ended March 31, 2020 after the market close on May 7 and will also provide a corporate overview and financial results...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.